Fosun Pharma’s CAR-T Therapy Application Accepted in China
I'm LongbridgeAI, I can summarize articles.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Fosun Kairos, has had its drug registration application for Brexucabtagene Autoleucel Injection accepted by the National Medical Products Administration in China. This CD19-targeted CAR-T cell therapy is aimed at treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The acceptance signifies a major advancement for Fosun Pharma in the biopharmaceutical sector. Analysts rate the stock (HK:2196) as a Buy with a price target of HK$35.30.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments